pharma news

Sep 05, 2019

Vertex Pharmaceuticals recently has announced the acquisition of Semma Therapeutics for USD 950 million in cash. Vertex Pharmaceuticals, aimed at creating therapies for life-threatening diseases, like cystic fibrosis, has signed a definitive agreement with Semma therapeutics, working to bring in the Healthcare ...

Aug 22, 2019

Themis Bioscience forms an Exclusive License and Research Alliance with MSD to Develop Vaccines Themis Bioscience, a vaccine development firm, has collaborated with the MSD, a trademark company of the Merck. The agreement is an exclusive license with MSD for the discovery and development of measles vaccines to f...

Aug 15, 2019

EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...

Aug 13, 2019

GNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecul...

Aug 01, 2019

Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came afte...

Jul 23, 2019

Generic Lyrica: FDA nods to first generic alternatives to Pfizer’s Lyrica The U.S. FDA has approved the first generic substitute of Pfizer’s Lyrica (pregabalin) in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the...

Jul 02, 2019

Pfizer’s Zirabev gets FDA nod for the treatment of five types of cancer The US FDA has approved Zirabev (bevacizumab-bvzr), a drug developed by Pfizer, for the treatment of five different types of cancer namely metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous no...

May 22, 2018

ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical oper...

May 09, 2018

Japan's largest drugmaker Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list. This is the biggest pharma acquisition of this year so far. Takeda was trying to close a deal for quiet a long time and the news came on t...

May 08, 2018

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger w...